ImaginAb has started the clinical trial of its lead product, CD8 tracer Zr-Df-IAB22M2C, a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells.
Ian Wilson, CEO of ImaginAb, said their goals is to provide target-specific imaging agents to predict, inform, monitor and enable treatment of cancer disease more effectively. “We are delighted to add, the world-renowned, Dana-Farber Cancer Institute to our CD8 Imaging Phase II trial and for enrollment and imaged of their first patient in this ongoing clinical study,” he said.
The trial will enroll metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb’s CD8 T cell ImmunoPET imaging agent, standard-of-care scans, and immunohistochemistry analysis of CD8 in biopsied tissues, the company said in the press release. The trial will also measure changes in CD8+ T-cell distribution before and after immuno-oncology therapies.